A Smits1, E Westerberg, D Ribom. 1. Department of Neuroscience, Neurology, University Hospital, 751 85, Uppsala, Sweden. anja.smits@neurologi.uu.se
Abstract
PURPOSE: The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system. METHODS: In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups. RESULTS: In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours. CONCLUSIONS: Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
PURPOSE: The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system. METHODS: In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups. RESULTS: In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours. CONCLUSIONS: Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
Authors: G Bauman; K Lote; D Larson; L Stalpers; C Leighton; B Fisher; W Wara; D MacDonald; L Stitt; J G Cairncross Journal: Int J Radiat Oncol Biol Phys Date: 1999-11-01 Impact factor: 7.038
Authors: D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits Journal: Cancer Date: 2001-09-15 Impact factor: 6.860
Authors: E Shaw; R Arusell; B Scheithauer; J O'Fallon; B O'Neill; R Dinapoli; D Nelson; J Earle; C Jones; T Cascino; D Nichols; R Ivnik; R Hellman; W Curran; R Abrams Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee Journal: J Neuropathol Exp Neurol Date: 2002-03 Impact factor: 3.685
Authors: M Bergström; H Lundqvist; K Ericson; A Lilja; P Johnström; B Långström; H von Holst; L Eriksson; G Blomqvist Journal: Acta Radiol Date: 1987 May-Jun Impact factor: 1.990
Authors: Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2012-12-12 Impact factor: 9.236
Authors: Egesta Lopci; Marco Riva; Laura Olivari; Fabio Raneri; Riccardo Soffietti; Arnoldo Piccardo; Alberto Bizzi; Pierina Navarria; Anna Maria Ascolese; Roberta Rudà; Bethania Fernandes; Federico Pessina; Marco Grimaldi; Matteo Simonelli; Marco Rossi; Tommaso Alfieri; Paolo Andrea Zucali; Marta Scorsetti; Lorenzo Bello; Arturo Chiti Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-21 Impact factor: 9.236
Authors: T Kato; J Shinoda; N Oka; K Miwa; N Nakayama; H Yano; T Maruyama; Y Muragaki; T Iwama Journal: AJNR Am J Neuroradiol Date: 2008-08-07 Impact factor: 3.825
Authors: Nina Poetsch; Adelheid Woehrer; Johanna Gesperger; Julia Furtner; Alexander R Haug; Dorothee Wilhelm; Georg Widhalm; Georgios Karanikas; Michael Weber; Ivo Rausch; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Matthias Preusser; Tatjana Traub-Weidinger Journal: Neuro Oncol Date: 2018-02-19 Impact factor: 12.300
Authors: Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: J Neurooncol Date: 2015-11-03 Impact factor: 4.130